Is it real of lower incidence of vitamin D deficiency in T2DM patients?

Li, Yiu‐Tai; Yang, Szu‐Ting; Wang, Peng-Hui

doi:10.1097/jcma.0000000000000776

Cited by 8 publications

(8 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many patients with type 2 diabetes mellitus (T2DM) need oral antidiabetic drug treatment for blood sugar control and to avoid or delay the T2DM-related complications that could damage the microvascular and macrovascular circulatory systems and subsequently develop various kinds of morbidities and eventually mortality. 1 We read Dr. Chang’s study, 2 editorial comments by Dr. Lee et al, 3 and a letter to Editors by Dr. Lee et al 4 to discuss the extraglycemic benefits of oral antidiabetic drugs, including dipeptidyl peptidase-4 inhibitors (DPP-4i) in patients with T2DM. We found with interest that all patients with T2DM treated with DPP-4i took advantage of the lowering risk of the development of osteoporosis, as shown by the authors, but it is important to note that the advantages of decreasing the risk of osteoporosis are different between the male and female populations.…”

Section: Dear Editormentioning

confidence: 99%

Different genders should be considered for the extraglycemic benefits of oral antidiabetic drugs

Chang

Liu

2022

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

Section: Dear Editormentioning

confidence: 99%

Different genders should be considered for the extraglycemic benefits of oral antidiabetic drugs

Chang

Liu

2022

Journal of the Chinese Medical Association

View full text Add to dashboard Cite

“…Diabetes mellitus (DM), including type 1 DM (T1DM) and type 2 DM (T2DM), is a common but complex disease, associated with lots of comorbidities and a leading cause of mortality. [1][2][3][4][5][6][7][8] Risk factors associated with developing DM, especially T2DM accounting for >90% of all cases of DM worldwide, include elderly population, [9][10][11] family history (multiple genes), [11][12][13][14][15][16][17][18] overweight, 3,4,[17][18][19][20][21] obesity, 3,4,[17][18][19][20][21] pregnancy, such as the development of gestational DM, [21][22][23][24] dietary (calories intake, fibers, essential micronutrition, and mineral elements), [25][26][27][28][29] lifestyle factors (exercise, rest, and others), 3,4,[30][31][32]<...…”

Section: Introductionmentioning

confidence: 99%

To do one and to get more: Part I. Diabetes and bone

Lee

Wang

Yang

et al. 2022

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2DM), is a chronic metabolic disease, characterized by the presence of hyperglycemia and insulin resistance. The key treatment strategies for T2DM include modification of lifestyle, medications, and continuous glucose monitoring. DM patients often have DM-associated morbidities and comorbidities; however, disorders of musculoskeletal system are often neglected, compared to other major systems in DM patients. Based on sharing similar pathophysiology of DM and osteoporosis, it is supposed that the use of antidiabetic agents (ADAs) may not only provide the lowering glucose level effect and the maintenance of the sugar homeostasis to directly delay the tissue damage secondary to hyperglycemia but also offer the benefits, such as the prevention of developing osteoporosis and fractures. Based on the current review, evidence shows the positive correlation between DM and osteoporosis or fracture, but the effectiveness of using ADA in the prevention of osteoporosis and subsequent reduction of fracture seems to be inconclusive. Although the benefits of ADA on bone health are uncertain, the potential value of "To do one and to get more" therapeutic strategy should be always persuaded. At least, one of the key treatment strategies as an establishment of healthy lifestyle may work, because it improves the status of insulin resistance and subsequently helps DM control, prevents the DM-related micro-and macrovascular injury, and possibly strengthens the general performance of musculoskeletal system. With stronger musculoskeletal system support, the risk of "fall" may be decreased, because it is associated with fracture. Although the ADA available in the market does not satisfy the policy of "To do one and to get more" yet, we are looking forward to seeing the continuously advanced technology of drug development on diabetic control, and hope to see their extra-sugar-lowering effects.

show abstract

“…[36][37][38] In part I, we try to demonstrate the policy as "To do one and to get more" in the management of complicated diseases, such as DM, and hope that one therapeutic approach can provide more benefits beyond the sugar-lowering effect, 1 but unfortunately, evidence about the impact of ADA on DM and bone health (prevention of osteoporosis and reduction of fracture) seemed to be relatively disappointing, based on failure to show that the use of ADA can satisfy this proposal as "To do one and to get more" concept. 1,[39][40][41] Uncertain conclusions are made after reviewing recent publications from the systemic review and meta-analyses to address the effect of ADA on both DM and bone health. 1,[42][43][44] We still optimized the unlimited potential ability of ADA on ameliorating bone loss (osteoporosis) and preventing fracture, because advance of biomedical technology for ADA can be continuously and uninterruptedly progressed and this dream may come true.…”

Section: Introductionmentioning

confidence: 99%

To Do One and To Get More: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases

Lee

Wang

Yang

et al. 2022

Journal of the Chinese Medical Association

Self Cite

View full text Add to dashboard Cite

Type 2 diabetes mellitus (DM) is characterized by inability of faulty pancreatic β-cells to secret a normal amount of insulin to maintain normal body consumption, and/or peripheral tissue has a decreased susceptibility to insulin, resulting in hyperglycemia and insulin resistance. Similar to other chronic systemic inflammatory diseases, DM is a result from dysregulated interactions between ethnic, genetic, epigenetic, immunoregulatory, hormonal, and environmental factors. Therefore, it is rational to suppose the concept as “To do one and to get more”, while using antidiabetic agents (ADA), a main pharmacologic agent for the treatment of DM, can provide an extraglycemia effect on comorbidities or concomittent comorbidities to DM. In this review, based on the much strong correlation between DM and metabolic dysfunction-associated fatty liver diseases (MAFLD) shown by similar pathophysiological mechanisms and a high prevalence of DM in MAFLD and its vice versa (a high prevalence of MAFLD in DM), it is possible to use the strategy to target both diseases simultaneously. We focus on a new classification of ADA, such as glucagon-like peptide-1 receptor (GLP1R) agonist and sodium-glucose cotransporter-2 (SGLT-2) inhibitors to show the potential benefits of extraglycemic effect on MAFLD. We conclude that the management of DM patients, especially for those who need ADA as adjuvant therapy should include healthy lifestyle modification to overcome the metabolic syndrome, contributing to the urgent need of an effective weight-reduction strategy. GLP1R agonist is one of effective body weight-lowering medications, which may be a better choice for DM complicated with MAFLD or its-associated severe form as metabolic associated steatohepatitis (MASH), although the role of SGLT-2 inhibitors is also impressive. The prescription of these two classes of ADA may satisfy the concept “To do one and to get more”, based on successful sugar-lowering effect for controlling DM and extraglycemia benefits of hepatoprotective activity in DM patients.

show abstract

Is it real of lower incidence of vitamin D deficiency in T2DM patients?

Cited by 8 publications

References 7 publications

Different genders should be considered for the extraglycemic benefits of oral antidiabetic drugs

Different genders should be considered for the extraglycemic benefits of oral antidiabetic drugs

To do one and to get more: Part I. Diabetes and bone

To Do One and To Get More: Part II. Diabetes and metabolic dysfunction-associated fatty liver diseases

Contact Info

Product

Resources

About